When is Daratumumab's Patent Expected to Expire?
The primary patent covering daratumumab, the active ingredient in the multiple myeloma drug Darzalex, is set to expire in 2032 [1]. However, this expiration date can be influenced by various factors, including potential patent challenges and the granting of additional patents for new formulations or uses [2].
What Does Darzalex Treat?
Daratumumab, marketed as Darzalex, is a medication used to treat certain types of multiple myeloma [3]. Multiple myeloma is a cancer of plasma cells, a type of white blood cell that normally helps fight infection [4].
How Does Darzalex Work?
Daratumuxumab is a monoclonal antibody that targets a specific protein, CD38, found on the surface of myeloma cells [3]. By binding to CD38, it helps the immune system identify and destroy these cancer cells [3].
Who Makes Darzalex?
Daratumuxumab is developed and marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [3][5].
Are There Other Patents for Daratumumab?
Beyond the primary patent, there may be other patents related to daratumumab that cover specific aspects such as manufacturing processes, formulations, or new indications [2]. These secondary patents could extend market exclusivity for certain applications of the drug [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide detailed insights into the patent landscape for drugs like daratumumab [1][2].
What Happens When Darzalex's Patent Expires?
Upon the expiration of its primary patents, generic versions of daratumumab could potentially enter the market [2]. This typically leads to increased competition and a reduction in drug prices [2]. However, the exact timing of generic entry can depend on the strength and duration of any remaining secondary patents and the regulatory approval process for generic manufacturers [2].
What About Biosimilars?
As daratumumab is a biologic drug, the concept of biosimilars applies rather than generics. Biosimilars are highly similar to a reference biologic drug in terms of safety, purity, and potency [6]. The pathway for biosimilar approval in the United States is governed by the Biologics Price Competition and Innovation Act (BPCIA) [6]. The exclusivity period for biosimilars can vary, and litigation or patent challenges can impact their market entry [2][6].
Are There Any Current Patent Disputes Involving Darzalex?
Information regarding ongoing patent disputes for daratumumab is not publicly detailed in the provided context. However, pharmaceutical patent litigation is common, and companies frequently challenge patents to facilitate earlier market entry for their generic or biosimilar products [2].
How Much Does Darzalex Cost?
The cost of Darzalex can be significant, reflecting the research and development investment and the specialized nature of the treatment [5]. Pricing information can vary based on insurance coverage, geographic location, and treatment duration.
What Are the Potential Risks or Side Effects of Darzalex?
Common side effects associated with daratumumab treatment can include infusion reactions, fatigue, nausea, diarrhea, constipation, and upper respiratory tract infections [3]. Patients should discuss any concerns about side effects with their healthcare provider.
What Other Treatments Are Available for Multiple Myeloma?
Several other treatments are available for multiple myeloma, including other chemotherapy drugs, proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation [4]. The choice of treatment depends on the individual patient's condition and disease stage [4].
---
1. "Daratumumab." DrugPatentWatch.com.
2. "Daratumumab Patent Expiration." DrugPatentWatch.com.
3. "Darzalex Prescribing Information." Janssen Biotech, Inc.
4. National Cancer Institute. "Multiple Myeloma Treatment."
5. "Johnson & Johnson Reports Q1 2023 Results." Johnson & Johnson.
6. U.S. Food and Drug Administration. "Biosimilars."